Digest Network Come funziona
Network
/
Società
Pf
Non verificato

Pfizer Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

103 comunicati stampa

Guarda tutti i comunicati
09/03/2026
Industria
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis
Fonte
Pfizer Inc.
Emittente
Business Wire
1.00
0
27/02/2026
Mercato del lavoro
Industria
Oncologia
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
Fonte
Pfizer Inc.
Emittente
Business Wire
1.00
0
23/02/2026
Eventi
Web e Social Network
Scienza
Biotecnologia
Farmaceutica
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Fonte
Pfizer Inc.
Emittente
Business Wire
1.00
0
17/02/2026
Eventi
Industria
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
Fonte
Pfizer Inc.
Emittente
Business Wire
1.00
0
06/02/2026
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Industria
FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need
Fonte
Pfizer Inc.
Emittente
Business Wire
1.00
0
06/02/2026
Industria
Biotecnologia
Sanità
Farmaceutica
Salute
Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans
Fonte
Pfizer Inc.
Emittente
Business Wire
1.00
0
03/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
Fonte
Pfizer Inc.
Emittente
Business Wire
1.00
0
03/02/2026
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
Fonte
Pfizer Inc.
Emittente
Business Wire
1.00
0
05/01/2026
Eventi
Web e Social Network
Scienza
Biotecnologia
Farmaceutica
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Fonte
Pfizer Inc.
Emittente
Business Wire
1.00
0
18/12/2025
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
Fonte
Pfizer Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0